Cube Labs S.P.A. (IT:CUBE) has released an update.
Cube Labs’ subsidiary, Adamas Biotech, has secured official registration from Italy’s Ministry of Health for Theakine® Prost, a green tea-based supplement aimed at improving prostate health. The company plans to partner with firms in the urology sector for its distribution, rather than marketing it directly. This development signifies a strategic advancement in Cube Labs’ commercial endeavors within the healthcare sector.
For further insights into IT:CUBE stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) Hardware Is Starting to Lag
- Netflix (NASDAQ:NFLX) Celebrates Two Years of Ads with 70 Million Users
- Verizon (NYSE:VZ) Suffers Massive Outage
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
